profit from every $100 of sales.
$0$100
XOMA
We have no price for XOMA since 21 July 2026. It may have been taken over, merged or renamed, so the figures below are from then.
$25.00+0.00% today
-1.1% since Oct 10, 25
1-year low $24.961-year high $26.25
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
You pay $15.73 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
XOMA vs. similar companies
XOMA grows the slowest of these 5 and is the cheapest for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| XOMA | 15.7× · Fair price | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads XOMA's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisNo annual statements on file yet.
Valuation
- 15.7×
- 22.2×
- –
- 4.4×
- 14.4×
- 78.8×
- 13.2×
- 0.9%
- 6.4%
- 0.0%
Profitability
- 93.3%
- 13.7%
- 87.0%
- 115.5%
- 1.9%
- -3.0%
- 30.2%
- 11.6%
- 2.1%
- 1.3%
Growth
- +8.1%
- +22.0%
- +120.9%
- –
- +12.3%
Financial health
- 0.7×
- 1.10
- 45.9%
- 0.4×
- 3.59
- 3.59
- 0.13
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 42%of 946
Top 38%of 872
Top 21%of 563
Bottom 39%of 868
Bottom 48%of 986
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 12, 2026 | 0.18 | 0.17 | +7.3% |
| Mar 18, 2026 | 0.26 | -0.11 | +327.0% |
| Nov 12, 2025 | 0.78 | -0.04 | +2,037.5% |
| Aug 15, 2025 | 0.52 | -0.15 | +444.7% |
| May 13, 2025 | 0.20 | -0.24 | +183.2% |
| Mar 17, 2025 | -0.33 | -0.29 | −16.5% |
| Nov 7, 2024 | -1.47 | – | – |
| Aug 13, 2024 | 0.92 | – | – |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
39No pass
Benjamin Graham
50No pass
Philip Fisher
66Pass
Peter Lynch
79Pass
Joel Greenblatt
12No pass
Charlie Munger
46No pass
Terry Smith
45No pass
Questions about XOMA
Is XOMA a good stock to buy?
A strong, very profitable business at a fair price. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the XOMA AI analysis
What does XOMA do?
XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It is in Biotechnology.
Does XOMA pay a dividend?
No. XOMA does not pay a dividend at the moment.
Who are XOMA's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with XOMA's.
Prices: daily closes to Jul 21, 2026. Fundamentals: company reports via invest-like data.